MY185320A - Human antibodies to influenza hemagglutinin - Google Patents

Human antibodies to influenza hemagglutinin

Info

Publication number
MY185320A
MY185320A MYPI2017701896A MYPI2017701896A MY185320A MY 185320 A MY185320 A MY 185320A MY PI2017701896 A MYPI2017701896 A MY PI2017701896A MY PI2017701896 A MYPI2017701896 A MY PI2017701896A MY 185320 A MY185320 A MY 185320A
Authority
MY
Malaysia
Prior art keywords
antibodies
influenza
influenza hemagglutinin
human antibodies
bind
Prior art date
Application number
MYPI2017701896A
Other languages
English (en)
Inventor
Ngambo Lisa A Purcell
Jonathan Viau
William Olson
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MY185320A publication Critical patent/MY185320A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/108—Orthomyxoviridae (F), e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MYPI2017701896A 2014-12-19 2015-12-18 Human antibodies to influenza hemagglutinin MY185320A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462094752P 2014-12-19 2014-12-19
US201562152122P 2015-04-24 2015-04-24
PCT/US2015/066654 WO2016100807A2 (en) 2014-12-19 2015-12-18 Human antibodies to influenza hemagglutinin

Publications (1)

Publication Number Publication Date
MY185320A true MY185320A (en) 2021-05-04

Family

ID=55073153

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2017701896A MY185320A (en) 2014-12-19 2015-12-18 Human antibodies to influenza hemagglutinin

Country Status (19)

Country Link
US (3) US10392432B2 (enExample)
EP (1) EP3233908A2 (enExample)
JP (2) JP6711828B2 (enExample)
KR (1) KR102729973B1 (enExample)
CN (1) CN108064240B (enExample)
AU (1) AU2015364415B2 (enExample)
BR (1) BR112017012944A2 (enExample)
CA (1) CA2969749A1 (enExample)
CL (2) CL2017001610A1 (enExample)
CO (1) CO2017006580A2 (enExample)
EA (1) EA036953B1 (enExample)
IL (1) IL252659B (enExample)
MX (2) MX386403B (enExample)
MY (1) MY185320A (enExample)
PH (1) PH12017500949A1 (enExample)
SG (2) SG10202010170SA (enExample)
TW (2) TWI701258B (enExample)
UY (1) UY36458A (enExample)
WO (1) WO2016100807A2 (enExample)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9969794B2 (en) 2012-05-10 2018-05-15 Visterra, Inc. HA binding agents
TWI701258B (zh) 2014-12-19 2020-08-11 美商再生元醫藥公司 流行性感冒病毒血球凝集素之人類抗體
CA3015347A1 (en) 2016-02-24 2017-08-31 Visterra, Inc. Formulations of antibody molecules to influenza virus
EP3515491A4 (en) 2016-09-21 2020-09-16 Aptevo Research and Development LLC CD123 BINDING PROTEINS AND RELATED COMPOSITIONS AND PROCESSES
US11667697B2 (en) 2016-10-19 2023-06-06 Vanderbilt University Human orthopoxvirus antibodies and methods of use therefor
TW202311284A (zh) * 2017-01-03 2023-03-16 美商再生元醫藥公司 抗金黃色葡萄球菌溶血素ａ毒素之人類抗體
WO2019006162A1 (en) 2017-06-28 2019-01-03 Bluefin Biomedicine, Inc. ANTI-LY6H ANTIBODIES AND CONJUGATES ANTIBODY-MEDICINE
MX2020001879A (es) * 2017-08-18 2020-07-29 Gritstone Oncology Inc Proteínas de fijación al antígeno que se dirigen a antígenos compartidos.
EP3638698B1 (en) * 2018-01-26 2021-03-03 Regeneron Pharmaceuticals, Inc. Anti-tmprss2 antibodies and antigen-binding fragments
SG11202006379UA (en) 2018-01-26 2020-07-29 Regeneron Pharma Human antibodies to influenza hemagglutinin
EP3758749A4 (en) 2018-03-02 2022-07-06 The University of Chicago METHOD AND COMPOSITION FOR NEUTRALIZING INFLUENZA
KR20200060969A (ko) * 2018-11-23 2020-06-02 (주)셀트리온 인플루엔자 바이러스 질환을 치료하기 위한 투여 요법
JP2022519631A (ja) 2019-02-12 2022-03-24 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 補体および標的抗原に結合する二重特異性抗体を使用するための組成物および方法
EP3946613A1 (en) * 2019-03-25 2022-02-09 Visterra, Inc. Compositions and methods for treating and preventing influenza
EP3945800A1 (en) 2019-04-03 2022-02-09 Regeneron Pharmaceuticals, Inc. Methods and compositions for insertion of antibody coding sequences into a safe harbor locus
JP7634231B2 (ja) 2019-05-31 2025-02-21 ワシントン ユニバーシティ Ｐａｎ－ノイラミニダーゼ阻害抗体
US20220298230A1 (en) * 2019-06-11 2022-09-22 The Rockefeller University Antibodies and methods for treatment of viral infections
EP4010021A4 (en) * 2019-08-06 2023-08-30 Regents of the University of Minnesota COMPOSITIONS AND METHODS FOR TREATING SERPINE B13 DISORDERS
JP7611908B2 (ja) * 2019-10-28 2025-01-10 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 抗血球凝集素抗体およびその使用方法
MX2022008901A (es) * 2020-01-24 2022-08-16 Regeneron Pharma Conjugados de proteinas-compuestos antivirales.
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
AU2021219671A1 (en) * 2020-02-10 2022-07-14 Regeneron Pharmaceuticals, Inc. Anti-Tmprss2 Antibodies and Antigen-Binding Fragments
WO2021195418A1 (en) 2020-03-26 2021-09-30 Vanderbilt University Human monoclonal antibodies to severe acute respiratory syndrome coronavirus 2 (sars-cov-2)
US20230122364A1 (en) * 2020-03-27 2023-04-20 Vanderbilt University HUMAN MONOCLONAL ANTIBODIES TO SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-CoV-2)
CN117050175B (zh) * 2020-04-17 2024-07-16 珠海泰诺麦博制药股份有限公司 抗人神经生长因子的抗体
BR112022021780A2 (pt) 2020-04-27 2023-03-07 Twist Bioscience Corp Bibliotecas de ácido nucléico variantes para coronavírus
WO2022082030A2 (en) 2020-10-15 2022-04-21 Gritstone Bio, Inc. Antigen-binding proteins and related methods of use
US20230391856A1 (en) * 2020-10-23 2023-12-07 Icahn School Of Medicine At Mount Sinai Sars-cov-2 antibodies and uses thereof
KR20230135569A (ko) * 2020-11-23 2023-09-25 비르 바이오테크놀로지, 인코포레이티드 인플루엔자 a 바이러스에 대한 항체
WO2022155503A1 (en) 2021-01-14 2022-07-21 Gritstone Bio, Inc. Multi-specific antibodies and methods of use
KR102604669B1 (ko) * 2021-03-30 2023-11-21 충남대학교산학협력단 조류인플루엔자 바이러스의 ha 단백질에 특이적인 단클론항체, 및 이의 용도
KR20240038928A (ko) 2021-07-28 2024-03-26 리제너론 파마슈티칼스 인코포레이티드 단백질-항바이러스 화합물 접합체
EP4396235A4 (en) * 2021-09-02 2025-07-02 Memorial Sloan Kettering Cancer Center ANTI-CD33 ANTIBODIES AND THEIR USES
US20250059260A1 (en) * 2021-12-22 2025-02-20 The University Of Chicago Methods for detecting or treating influenza infections
MX2024008361A (es) 2022-01-14 2024-09-10 Regeneron Pharma Derivados de verrucarina a y conjugados anticuerpo-fármaco de los mismos.
EP4626553A2 (en) 2022-11-30 2025-10-08 Regeneron Pharmaceuticals, Inc. Tlr7 agonists and antibody-drug-conjugates thereof
CN115993452B (zh) * 2023-03-23 2023-06-16 深圳市卫光生物制品股份有限公司 一种流感病毒疫苗血凝素含量测定方法及试剂盒
EP4791784A1 (en) * 2023-10-13 2026-08-19 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Anti-ny-eso-1 antibodies and uses thereof
WO2025117727A1 (en) 2023-11-29 2025-06-05 Regeneron Pharmaceuticals, Inc. Analogs of quinoxaline/quinoline cytotoxins, linker- payloads, protein-drug conjugates, and uses thereof
WO2025160340A2 (en) 2024-01-26 2025-07-31 Regeneron Pharmaceuticals, Inc. Combination immunosuppression for inhibiting an immune response and enabling immunogen administration and re-administration
US20250242056A1 (en) 2024-01-26 2025-07-31 Regeneron Pharmaceuticals, Inc. Methods and compositions for using plasma cell depleting agents and/or b cell depleting agents to suppress host anti-aav antibody response and enable aav transduction and re-dosing
WO2025166216A1 (en) * 2024-02-02 2025-08-07 The Board Of Regents Of The University Of Texas System Trop2-targeting antibodies and uses thereof
WO2025184137A1 (en) * 2024-02-27 2025-09-04 Adimab, Llc Influenza antibodies and methods of use thereof
WO2025184567A1 (en) 2024-03-01 2025-09-04 Regeneron Pharmaceuticals, Inc. Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response
WO2025255258A2 (en) * 2024-06-05 2025-12-11 Vaxart, Inc. Antibodies targeting gii genotypes of human norovirus

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5589174A (en) 1992-09-17 1996-12-31 Takara Shuzo Co., Ltd. Anti-human influenza virus antibody
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
EP1740946B1 (en) 2004-04-20 2013-11-06 Genmab A/S Human monoclonal antibodies against cd20
US8257740B1 (en) 2011-08-15 2012-09-04 Gp Medical, Inc. Pharmaceutical composition of nanoparticles
US8246995B2 (en) 2005-05-10 2012-08-21 The Board Of Trustees Of The Leland Stanford Junior University Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells
ATE537190T1 (de) 2006-06-02 2011-12-15 Regeneron Pharma Hochaffine antikörper gegen den humanen il-6- rezeptor
CA2663388C (en) 2006-09-07 2017-01-17 Crucell Holland B.V. Human binding molecules capable of neutralizing influenza virus h5n1 and uses thereof
CN102046654A (zh) 2007-03-13 2011-05-04 胡马斯有限公司 针对甲型流感病毒h5n1株系的抗体
JP5597128B2 (ja) 2007-05-11 2014-10-01 テマセック・ライフ・サイエンシズ・ラボラトリー・リミテッド Ｈ５トリインフルエンザの診断および監視に有用なｈ５亜型特異的結合タンパク質
CN103254308B (zh) 2007-06-15 2015-01-21 厦门大学 H5亚型禽流感病毒血凝素蛋白的单克隆抗体或其结合活性片段及其用途
US8383121B2 (en) 2007-09-13 2013-02-26 Temasek Life Sciences Laboratory Limited Monoclonal antibodies specific to hemagglutinin and neuraminidase from influenza virus H5-subtype or N1-subtype and uses thereof
JP5490695B2 (ja) 2007-09-13 2014-05-14 テマセック・ライフ・サイエンシズ・ラボラトリー・リミテッド インフルエンザウイルスｈ５亜型からのヘマグルチニンに特異的なモノクローナル抗体およびそれらの使用
FR2921928B1 (fr) 2007-10-08 2011-03-04 Sanofi Pasteur Anticorps monoclonaux specifiques de l'hemagglutinine du virus grippal
EP3524619A1 (en) 2007-12-06 2019-08-14 Dana-Farber Cancer Institute, Inc. Antibodies against influenza virus and methods of use thereof
JP5490725B2 (ja) 2008-02-05 2014-05-14 テマセック・ライフ・サイエンシズ・ラボラトリー・リミテッド Ｈ５亜型インフルエンザウイルスの普遍的な検出のための結合タンパク質およびエピトープブロッキングｅｌｉｓａ
WO2009111865A1 (en) 2008-03-12 2009-09-17 Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of Health Reagents and methods for detecting influenza virus proteins
ITTO20080204A1 (it) 2008-03-17 2009-09-18 Pomona Biotechnologies Llc Anticorpi monoclonali atti a reagire con una pluralita di sottotipi del virus influenzale a
CA2719201A1 (en) 2008-03-28 2009-10-01 Sea Lane Biotechnologies, Llc. Neutralizing molecules to viral antigens
CN101990575B (zh) 2008-03-28 2015-06-17 国立大学法人北海道大学 抗h5亚型a型流感病毒血凝素单克隆抗体
ITTO20080398A1 (it) 2008-05-27 2009-11-28 Pomona Biotechnologies Llc Anticorpi monoclonali aventi proprieta' di cross-neutralizzazione omosubtipica per virus influenzali di tipo a sottotipo h1
CA2731686C (en) 2008-07-25 2020-04-07 Institute For Research In Biomedicine Neutralizing anti-influenza a virus antibodies and uses thereof
US8871207B2 (en) 2008-07-25 2014-10-28 Humabs, LLC Neutralizing anti-influenza A virus antibodies and uses thereof
US20120128684A1 (en) 2008-08-25 2012-05-24 Burnham Institute For Medical Research Conserved Hemagglutinin Epitope, Antibodies to the Epitope and Methods of Use
AU2008365616A1 (en) 2008-12-24 2011-08-11 Temasek Life Sciences Laboratory Limited Monoclonal antibodies specific to the fusion peptide from hemagglutinin from influenza A viruses and uses thereof
EP2380976A4 (en) 2008-12-25 2012-11-07 Univ Osaka HUMAN ANTIBODY AGAINST HUMAN FLUX VIRUS
US8894997B2 (en) 2009-04-30 2014-11-25 Vanderbilt University Monoclonal antibodies to influenza H1N1 virus uses thereof
KR101790354B1 (ko) 2009-05-11 2017-10-25 얀센 백신스 앤드 프리벤션 비.브이. 인플루엔자 바이러스 ｈ3ｎ2를 중화시킬 수 있는 인간 결합 분자 및 그것의 용도
US20120128671A1 (en) 2009-05-13 2012-05-24 Lawrence Horowitz Neutralizing molecules to influenza viruses
JP5941841B2 (ja) 2009-05-26 2016-06-29 アイカーン スクール オブ メディシン アット マウント サイナイ 周期的投与によって作製されたインフルエンザウイルスに対するモノクローナル抗体及びその使用
TWI507525B (zh) 2009-06-26 2015-11-11 Regeneron Pharma 具天然免疫球蛋白形式之易分離的雙專一性抗體
EP2464383A4 (en) 2009-08-14 2013-02-13 Theraclone Sciences Inc COMPOSITIONS AND METHODS FOR THE THERAPY AND DIAGNOSIS OF GRIP
US8784819B2 (en) 2009-09-29 2014-07-22 Ibio Inc. Influenza hemagglutinin antibodies, compositions and related methods
SG183149A1 (en) 2010-02-08 2012-09-27 Regeneron Pharma Common light chain mouse
CN102791734B (zh) 2010-03-08 2014-10-15 赛特瑞恩股份有限公司 源自人b细胞且具有抗甲型流感病毒的中和活性的人单克隆抗体
HRP20170490T1 (hr) 2010-03-26 2017-06-02 Pomona Ricerca S.R.L. Imunoglobulini pune dužine igg izotipa sposobni za prepoznavanje heterosubtipnog epitopa neutralizacije na području stabljike hemaglutinina i njihova uporaba kao lijek protiv gripe
RU2635999C2 (ru) 2010-06-17 2017-11-17 ТРЕЛЛИС БАЙОСАЙЕНС, ЭлЭлСи Антитела, подходящие для пассивной иммунизации против гриппа
EP2603237A4 (en) 2010-08-12 2014-05-21 Theraclone Sciences Inc ANTI-HEMAGGLUTININE ANTIBODY COMPOSITIONS AND METHOD FOR THEIR USE
JP6101204B2 (ja) 2010-08-23 2017-03-22 テマセック・ライフ・サイエンシズ・ラボラトリー・リミテッド インフルエンザｈ５赤血球凝集素の主要中和エピトープに特異的なモノクローナル抗体
US9534042B2 (en) 2010-09-03 2017-01-03 Fujita Health University Influenza virus-neutralizing antibody and screening method therefor
WO2012045001A2 (en) 2010-09-30 2012-04-05 Vanderbilt University Influenza virus antibodies and immunogens and uses therefor
US8900585B2 (en) 2010-10-20 2014-12-02 New York Blood Center, Inc. Influenza hemagglutinin-specific monoclonal antibodies for preventing and treating influenza virus infection
AU2012217867A1 (en) 2011-02-14 2013-09-05 Theraclone Sciences, Inc. Compositions and methods for the therapy and diagnosis of influenza
EP2731967B1 (en) 2011-07-14 2016-10-12 Janssen Vaccines & Prevention B.V. Human binding molecules capable of neutralizing influenza a viruses of phylogenetic group 1 and phylogenetic group 2 and influenza b viruses
HUE044089T2 (hu) * 2011-07-18 2019-09-30 Inst Res Biomedicine Neutralizáló anti-influenza A antitestek és alkalmazásaik
WO2013081463A2 (en) 2011-12-02 2013-06-06 Aimm Therapeutics B.V. Influenza a virus specific antibodies
MX360056B (es) 2012-03-08 2018-10-19 Janssen Vaccines & Prevention Bv Moléculas de unión humanas que pueden unirse a los virus de la influenza b y neutralizarlos, y sus usos.
AU2013260123A1 (en) 2012-05-10 2014-11-13 Massachusetts Institute Of Technology Agents for influenza neutralization
US9969794B2 (en) 2012-05-10 2018-05-15 Visterra, Inc. HA binding agents
US20140086927A1 (en) 2012-09-25 2014-03-27 Fujita Health University Novel epitope and mechanism of antigen-antibody interaction in an influenza virus
BR112015010817A8 (pt) * 2012-11-13 2018-01-23 Genentech Inc anticorpos anti-hemaglutinina isolado, método de tratamento, inibição ou prevenção de infecções, composição, composição farmacêutica, ácido nucleico isolado, célula hospedeira, método de produção de anticorpos e uso do anticorpo anti-hemaglutinina
KR20140118682A (ko) 2013-03-29 2014-10-08 (주)셀트리온 2 이상의 인플루엔자 ａ 바이러스 중화 결합 분자를 포함하는 조성물
SG11201602522VA (en) 2013-10-02 2016-04-28 Medimmune Llc Neutralizing anti-influenza a antibodies and uses thereof
TWI701258B (zh) 2014-12-19 2020-08-11 美商再生元醫藥公司 流行性感冒病毒血球凝集素之人類抗體
EP3638698B1 (en) * 2018-01-26 2021-03-03 Regeneron Pharmaceuticals, Inc. Anti-tmprss2 antibodies and antigen-binding fragments

Also Published As

Publication number Publication date
WO2016100807A3 (en) 2016-08-04
EA036953B1 (ru) 2021-01-19
MX2017008186A (es) 2018-02-09
CO2017006580A2 (es) 2017-09-29
CL2017001610A1 (es) 2018-03-09
TW201632548A (zh) 2016-09-16
MX2021007679A (es) 2021-08-05
CN108064240B (zh) 2022-01-04
IL252659B (en) 2021-06-30
EA201791086A1 (ru) 2018-01-31
AU2015364415B2 (en) 2021-09-02
US10392432B2 (en) 2019-08-27
JP6711828B2 (ja) 2020-06-17
SG11201704212SA (en) 2017-06-29
JP2018503361A (ja) 2018-02-08
US20200017576A1 (en) 2020-01-16
US20200377575A1 (en) 2020-12-03
BR112017012944A2 (pt) 2018-05-15
US10689436B2 (en) 2020-06-23
TWI701258B (zh) 2020-08-11
US11453714B2 (en) 2022-09-27
TW202026310A (zh) 2020-07-16
AU2015364415A1 (en) 2017-06-15
CL2019002196A1 (es) 2019-12-13
MX386403B (es) 2025-03-04
TWI702229B (zh) 2020-08-21
KR102729973B1 (ko) 2024-11-14
US20160176953A1 (en) 2016-06-23
PH12017500949A1 (en) 2017-10-02
CN108064240A (zh) 2018-05-22
WO2016100807A2 (en) 2016-06-23
SG10202010170SA (en) 2020-11-27
EP3233908A2 (en) 2017-10-25
CA2969749A1 (en) 2016-06-23
UY36458A (es) 2016-07-29
IL252659A0 (en) 2017-07-31
KR20170098888A (ko) 2017-08-30
JP2019055996A (ja) 2019-04-11

Similar Documents

Publication Publication Date Title
PH12017500949A1 (en) Human antibodies to influenza hemagglutinin
PH12018502673A1 (en) Anti-zika virus antibodies and methods of use
MX2017009716A (es) Anticuerpos humanos contra glicoproteina del virus ebola.
PH12018501281A1 (en) Human immunodeficiency virus neutralizing antibodies
MX392098B (es) Anticuerpos neutralizantes de poliomavirus.
PH12020551051A1 (en) Human antibodies to influenza hemagglutinin
EA201790771A1 (ru) Фармацевтические композиции длительного действия для лечения гепатита c
PH12017501943B1 (en) Influenza virus neutralizing peptidomimetic compounds
MY207220A (en) Anti-hemagglutinin antibodies and methods of use thereof
HK1238655A1 (en) Human antibodies to influenza hemagglutinin
HK1240605A1 (zh) 针对埃博拉病毒糖蛋白的人抗体
EA202191973A2 (ru) Человеческие антитела к гликопротеину вируса эбола
EA201990300A1 (ru) Антитела к вирусу зика и способы их применения
IL240241B (en) Antibodies directed to bacillus anthracis protective antigen